References
- Rao AV, Balachandran B. Role of oxidative stress and antioxidants in neurodegenerative diseases. Nutr. Neurosci.5, 291–309 (2002).
- Halliwell B. Oxidative stress and neurodegeneration: where are we now? J. Neurochem.97, 1634–1658 (2006).
- Valko M, Rhodes CJ, Moncol J, Izaokovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress stress-induced cancer. Chem. Biol. Interact.160, 1–40 (2006).
- Wang JY, Wen LL, Huang YN, Chen YT, Ku MC. Dual effects of antioxidants in neurodegeneration: direct neuroprotection against oxidative stress and indirect protection via suppression of glia-mediated inflammation. Curr. Pharm. Des.12, 3521–3533 (2006).
- Emerit J, Edeas M, Bricaire F. Neurodegenerative diseases and oxidative stress. Biomed. Pharmacother.58, 39–46 (2004).
- Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine (Fourth Edition). Oxford University Press, Oxford, UK (2006).
- Linseman DA. Targeting oxidative stress for neuroprotection. Antioxidants Redox Signal.11, 421–423 (2009).
- Markesbery WR. Oxidative stress hypothesis in Alzheimer’s disease. Free Radic. Biol. Med.23, 134–147 (1997).
- Reynolds A, Laurie C, Mosley RL, Gendelman HE. Oxidative stress and the pathogenesis of neurodegenerative disorders. Int. Rev. Neurobiol.82, 297–325 (2007).
- Zhao B. Natural antioxidants protect neurons in Alzheimer’s disease and Parkinson’s disease. Neurochem. Res.34, 630–638 (2009).
- Mandel SA, Amit T, Weinreb O, Reznichenko L, Youdim MB. Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases. CNS Neurosci. Ther.14, 352–365, (2008).
- Mandel SA, Amit T, Kalfon L, Reznichenko L, Weinreb O, Youdim MB. Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG). J. Alzheimers Dis.15, 211–222 (2008).
- Avramovich-Tirosh Y, Reznichenko L, Mit T et al. Neurorescue activity, APP regulation and amyloid-β peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG. Curr. Alzheimer Res.4, 403–411 (2007).
- Mandel S, Amit T, Bar-Am O, Youdim MB. Iron dysregulation in Alzheimer’s disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective–neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog. Neurobiol.82, 348–360 (2007).
- Reznichenko L, Amit T, Zheng H et al. Reduction of iron-regulated amyloid precursor protein and β-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J. Neurochem.97, 527–536 (2006).
- Weinreb O, Mandel S, Amit T, Youdim MB. Neurological mechanisms of green tea polyphenols in Alzheimer‘s and Parkinson’s diseases. J. Nutr. Biochem.15, 506–516 (2004).
- Levites Y, Amit T, Mandel S, Youdim MB. Neuroprotection and neurorescue against Aβ toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J.17, 952–954 (2003).
- Mancuso C, Bates TE, Butterfield DA et al. Natural antioxidants in Alzheimer’s disease. Expert Opin. Investig. Drugs16, 1921–1931 (2007).
- Sun AY, Wang Q, Simonyi A, Sun GY. Botanical phenolics and brain health. Neuromol. Med.10, 259–274 (2008).
- Halliwell B. Biochemistry of oxidative stress. Inflammation35, 1147–1150 (2007).
- Seis H. Oxidative stress II. In: Oxidants and Antioxidants. Seis H (Ed.). Academic Press, London, UK (1991).
- Halliwell B, Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br. J. Pharmacol.142, 231–255 (2004).
- Cadenas E, Davies KJA. Mitochondrial free radical generation, oxidative stress and aging. Free Radic. Biol. Med.29, 222–230 (2000).
- Inoue M, Sato EF, Nishikawa M et al. Mitochondrial generation of reactive oxygen species and its role in aerobic life. Curr. Med. Chem.10, 2495–2505 (2003).
- Conner EM, Grisham MB. Inflammation, free radicals and antioxidants. Nutrition12, 274–277 (1996).
- Cadenas E. Biochemistry of oxygen toxicity. Ann. Rev. Biochem.58, 79–110 (1989).
- Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Radic. Biol. Med.11, 81–128 (1991).
- Stadtman ER. Role of oxidant species in aging. Curr. Med. Chem.11, 1105–1112 (2004).
- Squier TC, Bigelow DJ. Protein oxidation and age-dependent alterations in calcium homeostasis. Front. Biosci.5, D504–D506 (2000).
- Dizdaroglu M, Jaruga P, Birincioglu P, Rodrigues H. Free radical-induced damage to DNA: mechanisms and measurement. Free Radic. Biol. Med.32, 1102–1115 (2002).
- Halliwell B, Gutteridge JMC. The definition and measurement of antioxidants in biological systems. Free Radic. Biol. Med.18, 125–126 (1995).
- Floyd RA. Antioxidants, oxidative stress and degenerative neurological disorders. Proceed. Soc. Exp. Biol. Med.222, 236–245 (1999).
- Floyd RA. Role of oxygen free radicals in carcinogenesis and ischemia. FASEB J.4, 2587–2597 (1990).
- Raskin I, Ribnicky DM, Komarnytsky S et al. Plants and human health in the twenty-first century. Trends Biotech.20, 522–531 (2002).
- Bishayee A, Darvesh AS. Oxidative stress in cancer and neurodegenerative diseases: prevention and treatment by dietary antioxidants. In: Handbook of Free Radicals: Formation, Types and Effects. Kozyrev D, Slutsky V (Eds). Nova Science Publishers, NY, USA 1–55 (2010).
- Sun AY, Chen YM. Cancer chemoprevention with dietary phytochemicals. J. Biomed. Sci.5, 401–414 (1998).
- Kopec KK, Carroll RT. Alzheimer’s β-amyloid peptide 1–42 induced a phagocytic response in murine microglia. J. Neurochem.71, 2123–2131 (1998).
- Kopec KK, Carroll RT. Phagocytosis is regulated by nitric oxide in murine microglia. Nitric Oxide4, 103–111 (2000).
- Youdim MB, Geldenhuys WJ, Van der Schyf CJ. Why should we use multifunctional neuroprotection and neurorestorative drugs for Parkinson’s disease? Parkinsonism Relat. Disord.13, S281–S291 (2007).
- Cohen G, Werner P. Free radicals, oxidative stress and neurodegeneration. In: Neurodegenerative Diseases. Calne DB (Ed.). WB Saunders, PA, USA 139–162 (1994).
- Floyd RA, Carney JM. Free radical damage to protein and DNA: mechanisms involved and relevant observations on brain undergoing oxidative stress. Ann. Neurol.32, S22–S27 (1992).
- Shoulson I, Fahn S, Kieburtz K et al. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N. Engl. J. Med.328, 176–183 (1993).
- Yun HY, Dawson VL, Dawson TM. Neurobiology of nitric oxide. Crit. Rev. Neurobiol.10, 291–316 (1996).
- Ahmed R, Rasheed Z, Ahsan H. Biochemical and cellular toxicology of peroxynitrite: implications in cell death and autoimmune phenomenon. Immunopharmacol. Immunotoxicol.31, 388–396 (2009).
- Carroll RT, Galatsis P, Borosky S. 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (Tempol) inhibits peroxynitrite-mediated phenol nitration. Chem. Res. Toxicol.13, 294–300 (2000).
- Dabbeni-Sala F, DiSanto S, Franceschini D et al. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J.15, 164–170 (2001).
- Ogawa O, Zhu X, Perry G et al. Mitochondrial abnormalities and oxidative imbalance in neurodegenerative diseases. Sci. Aging Knowledge Environ.2002(41), pe16 (2002).
- Cash AD, Perry G, Ogawa O et al. Is Alzhemier’s disease a mitochondrial disorder? Neuroscientist8, 489–496 (2002).
- Mancuso C, Scapagnini G, Currò D et al. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front. Biosci.12, 1107–1123 (2007).
- Petrozzi L, Ricci G, Noemi JG et al. Mitochondria and neurodegenration. Biosci. Rep.27, 87–104 (2007).
- Chaturvedi RK, Beal MF. Mitochondrial approaches for neuroprotection. Ann. NY Acad. Sci.1147, 395–412 (2008).
- Wang J, Ho L, Zhao W et al. Moderate consumption of Cabernet Sauvignon attenuates Aβ neuropathology in a mouse model of Alzheimer’s disease. FASEB J.20, 2313–2320 (2006).
- Herbert LE, Scherr PA, Bienias JL et al. Alzheimer’s disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol.8, 1119–1122 (2003).
- Goedert M, Spillantini MG. A century of Alzheimer’s disease. Science314, 777–781 (2006).
- Contestabile A. The history of the cholinergic hypothesis. Behav. Brain Res. doi:10.1016/j.bbr.2009.12.044 (2010) (Epub ahead of print).
- Gibson GE, Karuppagounder SS, Shi Q. Oxidant-induced changes in mitochondria and calcium dynamic in the pathophysiology of Alzheimer’s disease. Ann. NY Acad. Sci.1147, 221–232 (2008).
- Praticò D. Evidence of oxidative stress in Alzheimer’s disease brain and antioxidant therapy. Lights and shadows. Mitochondria and oxidative stress in neurodegenerative disorders. Ann. NY Acad. Sci.1147, 70–78 (2008).
- Mangialasche F, Polidori MC, Monstero R et al. Biomarkers of oxidative and nitrosative damage in Alzheimer’s disease and mild cognitive impairment. Aging Res. Rev.8, 285–305 (2009).
- Markesbery WR, Ehmann WD. Brain trace elements in Alzheimer’s disease. In: Alzheimer’s Disease. Terry RD, Katzman R, Bick KL (Eds). Raven Press, NY, USA 353–367 (1993).
- Lovell MA, Ehmann WD, Butler SM et al. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer’s disease. Neurology45, 1594–1601 (1995).
- Markesbery WR, Carney JM. Oxidative alterations in Alzheimer’s disease. Brain Pathol.9, 133–146 (1999).
- Hensley K, Carney JM, Mattson MP et al. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer’s disease. Proc. Natl Acad. Sci. USA91, 3270–3274 (1994).
- Butterfield DA, Reed TT, Perluigi et al. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer’s disease. Brain Res.1148, 243–248 (2007).
- Mecocci P, MacGarvey U, Beal MF et al. Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease. Ann. Neurol.36, 747–751 (1994).
- Praticò D, Uryu K, Leight S et al. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci.21, 4183–4187 (2001).
- Feng Z, Qin C, Chang Y, Zhang J. Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer’s disease. Free Radic. Biol. Med.40, 101–109 (2006).
- Hensley K, Hall N, Subramaniam R et al. Brain regional correspondence between Alzheimer’s disease histopathology and biomarkers of protein oxidation. J. Neurochem.65, 2146–2156 (1995).
- Harris ME, Hensley K, Butterfield DA et al. Direct evidence of oxidative injury produced by the Alzheimer’s β-amyloid peptide (1–40) in cultured hippocampal neurons. Exp. Neurol.131, 193–202 (1995).
- Schulz JB, Matthews RT, Klockgether T et al. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol. Cell. Biochem.174, 193–197 (1997).
- Aliev G, Smith MA, de la Torre JC et al. Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer’s disease. Mitochondrion4, 649–663 (2004).
- Obrenovich ME, Smith MA, Seidlak SL et al. Overexpression of GRK2 in Alzheimer’s disease and in a chronic hypoperfusion rat model is an early marker of brain mitochondrial lesions. Neurotox. Res.10, 43–56 (2006).
- Long J, Gao F, Tong L et al. Mitochondrial decay in the brains of old rats: ameliorating effect of α-lipoic acid and acetyl-L-carnitine. Neurochem. Res.34, 755–763 (2008).
- Ansari MA, Scheff SW. Oxidative stress in the progression of Alzheimer’s disease in the frontal cortex. J. Neuropathol. Exp. Neurol.69, 155–167 (2010).
- Perez-Garcia E, Torrejon-Escribano B, Ferrer I. Dystrophic neuritis of senile plaques in Alzheimer’s disease are deficient in cytochrome C oxidase. Acta Neuropathol.116, 261–268 (2008).
- Bosetti F, Brizzi F, Barogi S. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer’s disease. Neurobiol. Aging23, 371–376 (2002).
- Terni B, Boada J, Portero-Otin M, Pamplona R, Ferrer I. Mitochondrial ATP-synthase in the entorhinal cortex is a target of oxidative stress at stages I/II of Alzheimer’s disease pathology. Brain Pathol. doi: 10.1111/j.1750-3639. 2009.00266.x (2009) (Epub ahead of print).
- Tamagno E, Parola M, Gulielmotto M. Multiple signaling events in amyloid β-induced, oxidative stress-dependent neuronal apoptosis. Free Radic. Biol. Med.35, 45–58 (2003).
- Reddy PH. Mitochondrial oxidative damage in aging and Alzheimer’s disease: implications for mitochondrially targeted antioxidant therapeutics. J. Biomed. Biotechnol.2006(3), 31372 (2006).
- Shenk JC, Liu J, Fischbach K et al. The effect of acetyl-L-carnitine and lipoic acid treatment in ApoE4 mouse as a model of human Alzheimer’s disease. J. Neurol. Sci.283, 199–206 (2009).
- Nishida Y, Ito S, Ohtsuki S. Depletion of vitamin E increases amyloid β accumulation by decreasing its clearance from brain and blood in a mouse model of Alzheimer’s disease. J. Biol. Chem.248, 33400–33408 (2009).
- Defeudis FV. Bilobalide and neuroprotection. Pharmacol. Res.46, 565–568 (2002).
- Kiewert C, Kumar V, Hildmann O et al. Role of glycine receptors and glycine release for the neuroprotective activity of bilobalide. Brain Res.1201, 143–150 (2008).
- Cyrus T, Praticò D. Vitamin E and atherosclerosis. In: The Encyclopedia of Vitamin E. Preedy VR, Watson RR (Eds). CABI Publishing, Wallingford, UK 623–632 (2006).
- Issac MG, Quinn R, Tabet N. Vitamin E for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst. Rev.3, CD002854 (2008).
- Lloret A, Badia MC, Mora NJ. Vitamin E paradox in Alzheimer’s disease: it does not prevent loss of cognition and may even be detrimental. J. Alzheimer’s Dis.17, 143–149 (2009).
- Williamson KS, Gabbita SP, Mou S et al. The nitration product 5-nitro-γ-tocopherol is increased in the Alzheimer brain. Nitric Oxide6, 221–227 (2002).
- Van Poppel G. Antioxidants and coronary heart disease. Ann. Med.26, 429–434 (1994).
- Fahad Ullah M, Khan MW. Food as Medicine: potential therapeutic tendencies of plant derived polyphenolic compounds. Asian Pacific J. Cancer Prev.9, 187–196 (2008).
- National Academy of Sciences, National Research Council. Diet, Nutrition and Cancer.National Academy Press, Washington, DC, USA (1982).
- Surh YJ. Cancer prevention with dietary phytochemicals. Nat. Rev. Cancer3, 768–780 (2003).
- Young VR. Dietary Reference Intakes.Proposed Definition and Plan for Review of Dietary Antioxidant and Related Compounds. National Academy Press, Washington, DC, USA (1998).
- Diplock AT, Charleux JL, Crozier-Willi G et al. Functional food science and defense against reactive oxidative species. Br. J. Nutr.80, S77–S112 (1998).
- Thurman DI. Antioxidants and pro-oxidants in malnourished populations. Proc. Nutr. Soc.48, 247–259 (1990).
- Bravo L. Polyphenols: chemistry, dietary sources, metabolism and nutritional significance. Nutr. Rev.56, 317–333 (1998).
- Ververidis F, Trantas E, Douglas C et al. Biotechnology of flavonoids and other phenylpropanoid-derived natural products. Part I. Chemical diversity, impacts on plant biology and human health. Biotechnol. J.2, 1214–1234 (2007).
- Korkina L. Phenylpropanoids as naturally occurring antioxidants: from plant defense to human health. Cell Mol. Biol.53, 15–25 (2008).
- Crozier A, Jaganath IB, Clifford MN. Dietary phenolics: chemistry, bio-availability and effects on health. Nat. Prod. Rep.26, 1001–1043 (2009).
- Bengmark S, Mesa MD, Gil A. Plant derived health: the effects of turmeric and curcuminoids. Nutr. Hosp.24, 273–281 (2009).
- Bisht K, Wagner KH, Bulmer AC. Curcumin, resveratrol and flavonoids as anti-inflammatory, cyto- and DNA-protective dietary compounds. Toxicology doi:10.1016/j.tox.2009.11.008 (2009) (Epub ahead of print).
- Joseph J, Cole G, Head E, Ingram D. Nutrition, brain aging and neurodegeneration. J. Neurosci.29, 12795–12801 (2009).
- Bastianetto S, Krantic S, Quinron R. Polyphenols as potential inhibitors of amyloid aggregation and toxicity: possible significance to Alzheimer’s disease. Mini Rev. Med. Chem.8, 429–435 (2008).
- Rossi L, Mazzitelli S, Arciello M et al. Benefits from dietary polyphenols from brain aging and Alzheimer’s disease. Neurochem. Res.33, 2390–2400 (2008).
- Inanami O, Asanuma T, Inukai N et al. The suppression of age-related accumulation of lipid peroxides in rat brain by administration of Rooibos tea (Aspalathus linearis). Neurosci. Lett.196, 85–88 (1995).
- Gottlieb M, Leal-Campanario R, Campos-Esparza MR et al. Neuroprotection by two polyphenols following excitotoxicity and experimental ischemia. Neurobiol. Dis.23, 374–386 (2006).
- Jung K, Lee B, Han SJ, Ryu JH, Kim DH. Mangiferin ameliorates scopolamine-induced learning deficits in mice. Biol. Pharm. Bull.32, 242–246 (2009).
- Campos-Esparza MR, Sánchez-Gómez MV, Matute C. Molecular mechanisms of neuroprotection by two natural antioxidant polyphenols. Cell Calcium45, 358–368 (2009).
- Cooke D, Steward WP, Gescher AJ, Marczylo T. Anthocyans from fruits and vegetables – does bright colour signal cancer chemopreventive activity? Eur. J. Cancer41, 1931–1940 (2005).
- Seeram N. Berry fruits: composition elements, biochemical activities and the impact of their intake on human health, performance and disease. J. Agric. Food Chem.56, 627–629 (2008).
- Stoner GD. Foodstuffs for preventing cancer: the preclinical and clinical development of berries. Cancer Prev. Res.2, 187–194 (2009).
- Wu X, Gu L, Prior RL, McKay S. Characterization of anthocyanins and proanthocyanidins in some cultivars of Ribes, Aronia, and Sambucus and their antioxidant capacity. J. Agric. Food Chem.52, 7846–7856 (2004).
- Trausadóttir T, Davies SS, Stock AA et al. Tart cherry juice decreased oxidative stress in healthy older men and women. J. Nutr.139, 1896–1900 (2009).
- Lansky EP, Newman RA. Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer. J. Ethnopharmacol.109, 177–206 (2007).
- Jurenka MT. Therapeutic application of pomegranate (Punica granatum L.): a review. Alt. Med. Rev.13, 128–144 (2008).
- Graham HN. Green tea composition, consumption, and polyphenol chemistry. Prev. Med.21, 334–350 (1992).
- Clement Y. Can green tea do that? A literature review of the clinical evidence. Prev. Med.49, 83–87 (2009).
- Schneider C, Segre T. Green tea: potential health benefits. Am. Fam. Physician79, 591–594 (2009).
- Guo S, Yan J, Yang T et al. Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson’s disease through inhibition of ROS-NO pathway. Biol. Psychiatry62, 1353–1362 (2007).
- Zaveri NT. Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. Life Sci.78, 2073–2080 (2006).
- Yoneda T, Hiramatsu M, Skamoto N et al. Antioxidant effects of “β catechins”. Biochem. Mol. Biol. Int.35, 995–1008 (1995).
- Chan YC, Hosoda K, Tsai CJ et al. Favorable effects of tea on reducing the cognitive deficits and brain morphological changes in senescence-accelerated mice. J. Nutr. Sci. Vitaminol. (Tokyo)52, 266–273 (2006).
- Schroeder EK, Kelsey NA, Doyle J et al. Green tea epigallocathechin 3-gallate accumulates in mitochondria and displays a selective antiapoptotic effect against inducers of mitochondrial oxidative stress in neurons. Antiox. Redox Signal.11, 469–479 (2009).
- Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell. Biol.41, 40–59 (2009).
- Ganguli M, Chandra V, Kamboh MI et al. Apolipoprotein E polymorphism and Alzheimer’s disease: the Indo–US Cross-National dementia study. Arch. Neurol.57, 824–830 (2000).
- Calabrese V, Bates TE, Mancuso C et al. Curcumin and the cellular stress response in free radical-related diseases. Mol. Food Nutr. Res.52, 1062–1073 (2008).
- Kim DS, Park SY, Kim JK. Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from βA (1–42) insult. Neurosci. Lett.303, 57–61 (2001).
- Jovanovic SV, Boone CW, Steenken S, Trinoga M, Kaskey RB. How curcumin works preferentially with water soluble antioxidants. J. Am. Chem. Soc.123, 3064–3068 (2001).
- Baum L, Ng A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer’s disease animal models. J. Alzheimers Dis.6, 367–577 (2004).
- Lee JS, Surh YJ. Nrf2 as a novel target for chemoprevention. Cancer Lett.224, 171–184 (2005).
- Garcia-Alloza M, Borelli LA, Rozkalne A, Hyman BT, Bacskai BJ. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restrores distorted neuritis in an Alzheimer mouse model. J. Neurochem.102, 1095–1104 (2007).
- Cole GM, Lim GP, Yang F et al. Prevention of Alzheimer’s disease: omega-3 fatty acid and phenolic anti-oxidant interventions. Neurobiol. Aging26, 133–136 (2005).
- Cole GM, Teter B, Frautschy SA. Neuroprotective effects of curcumin. Adv. Exp. Med. Biol.595, 197–212 (2007).
- McKay DL, Blumberg JB. A review of the bioactivity of South African herbal teas: rooibos (Aspalathus linearis) and honeybush (Cyclopia intermedia). Phytother Res.21, 1–16 (2007).
- Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res.49, 472–481 (2005).
- Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discovery5, 493–506 (2006).
- Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J.17, 1975–1985 (2003).
- Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the “French paradox”? Eur. J. Endocrinol.138, 619–620 (1998).
- Ferrieres J. The French Paradox; lessons from other countries. Heart90, 107–111 (2004).
- Harikumar KB, Aggarwal BB. Resveratrol: a multitargeted agent for age associated chronic diseases. Cell Cycle7, 1020–1037 (2008).
- Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev. Res.2, 409–418 (2009).
- Pirola L, Fröjdö S. Resveratrol: one molecule, many targets. IUBMB Life60, 323–332 (2008).
- de la Lastra C, Villegas I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem. Soc. Transact.35, 1156–1160 (2007).
- Han YS, Bastianetto S, Quirion R. Neuroprotective effects of resveratrol. In: Resveratrol in Health and Disease. Aggarwal BB, Shishodia S (Eds). CRC Press, FL, USA 619–630 (2006).
- Liu Y, Wang MW. Botanical drugs: challenges and opportunities: contribution to Linnaeus Memorial Symposium 2007. Life Sci.82, 445–449 (2008).
- Sánchez GM, Re L, Giuliani A, Núñez-Sellés AJ, Davison GP, León-Fernández OS. Protective effects of Mangifera indica L. extract, mangiferin and selected antioxidants against TPA-induced biomolecules oxidation and peritoneal macrophage activation in mice. Pharmacol. Res.42, 565–573 (2000).
- Kidd PM. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Altern. Med. Rev.14, 226–246 (2009).
- Pérez-Jiménez J, Serrano J, Tabernero M et al. Bioavailability of phenolic antioxidants associated with dietary fiber: plasma antioxidant capacity after acute and long-term intake in humans. Plant Foods Hum. Nutr.64, 102–107 (2009).
- Shao J, Li X, Lu X et al. Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells in mediated induction of intracellular reactive oxygen species levels. Colloid Surf. B: Biointerf.72, 40–47 (2009).
- Yadav VR, Suresh S, Devi K et al. Novel formulation of solid lipid microparticles of curcumin for anti-angiogenic and anti-inflammatory activity for optimization of therapy of inflammatory bowel disease. J. Pharm. Pharmacol.61, 311–321 (2009).
- Carroll RT, Bhatia D, Geldenhuys W et al. Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders. J. Drug Target. doi: 10.3109/10611861003639796 (2010) (Epub ahead of print).
- De Kok TM, van Breda SG, Manson MM. Mechanisms of combined action of different chemopreventive dietary compounds. Eur. J. Nutr.47, 51–59 (2008).
- Liu YG, Wang XD, Zhang XB. Effects of resveratrol on inflammatory processes induced by focal cerebral ischemia-reperfusion in rats. China J. Chinese Materia Medica32, 1792–1795 (2007).
- Joseph JA, Denisova NA, Arendash G et al. Blueberry supplementation enhances signaling and prevents behavioral deficits in an Alzheimer disease model. Nutr. Neurosci.6,153–162 (2003).
- Joseph JA, Fisher DR, Carey AN. Fruit extracts antagonize Aβ- or DA-induced deficits in Ca2+ flux in M1-transfected COS-7 cells. J. Alzheimers Dis.6, 403–411 (2004).
- Ramirez MR, Izquierdo I, do Carmo Bassols Raseira M et al. Effect of lyophilized Vaccinium berries on memory, anziety and locomotion in adult rats. Pharmacol. Res.52, 457–462 (2005).
- Zhu Y, Bickford PC, Sanberg P et al. Blueberry opposes β-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activation protein kinase. Rejuvenation Res.11, 891–901 (2008).
- Hartman RE, Shah A, Fagan AM et al. Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer’s disease. Neurobiol. Dis.24, 506–515 (2006).
- Lee SY, Lee JW, Lee Y et al. Inhibitory effect of green tea extract on β-amyloid-induced PC12 cell death by inhibition of the activation of NF-κB and ERK/p38 MAP kinase pathway through antioxidant mechanisms. Brain Res. Mol. Brain Res.140, 45–54 (2005).
- Rezai-Zadeh K, Shytle D, Sun N et al. Green tea epigallocathechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J. Neurosci.25, 8807–8814 (2005).
- Rezai-Zadeh K, Arendash GW, Hou H et al. Green tea epigallocathechin-3-gallate (EGCG) reduces β-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res.1214, 177–187 (2008).
- Lu JH, Guo J, Yang WH. Effects of green tea polyphenol on the behavior of Alzheimer’s disease like mice induced by D-galactose and Aβ25–35. Zhong Yao Cai29, 352–354 (2006).
- Bastianetto S, Zheng WH, Papadopoulos V et al.Neuroprotective effects of green and black teas and their catechins gallate esters against β-amyloid-induced toxicity. Eur. J. Neurosci.23, 55–64 (2006).
- Rassolijazi H, Joghataie MT, Roghani M et al. The beneficial effect of (-)-epigallocatechin-3-gallate in an experimental model of Alzheimer’s disease in rat: a behavioral analysis. Iran Biomed. J.11, 237–243 (2007).
- Haque AM, Hashimoto M, Katakura M et al. Green tea catechins prevent cognitive deficits caused Aβ1–40 in rats. J. Nutr. Biochem.19, 619–626 (2008).
- Ehrnhoefer DE, Bieschke M, Boeddrich A et al. EGCG redirects amyloidogenic polypeptides into unstructured, off pathway oligomers. Nat. Struct. Mol. Biol.15, 558–566 (2008).
- Lim GP, Chu T, Yang F et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci.21, 8370–8377 (2001).
- Ono K, Hasegawa K, Naiki H et al. Curcumin has potent anti-amyloidogenic effects for Alzheimer’s β-amyloid fibrils in vitro. J. Neurosci. Res.75, 742–750 (2004).
- Giri RK, Rajagopal V, Kalra VK. Curcumin, the active constituent of turmeric, inhibits amyloid peptide-induced cytochemokine gene expression and CCR5-mediated chemotaxis of THP-1 monocytes by modulating early growth response-1 transcription factor. J. Neurochem.91, 1199–1210 (2004).
- Yang F, Lim GP, Begum AN et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem.280, 5892–5901 (2005).
- Park SY, Kim HS, Cho EK et al. Curcumin protected PC12 cells against β-amyloid-induced toxicity and inhibition of oxidative damage and tau hyperphosphorylation. Food Chem. Toxicol.46, 2881–2887 (2008).
- Pan R, Qiu S, Lu DX, Dong J. Curcumin improves learning and memory ability and its neuroprotective mechanism. Chin. Med. J. (English)121, 832–839 (2008).
- Thomas P, Wang YJ, Zhong JH et al. Grape seed polyphenols and curcumin reduce genomic instability events in a transgenic mouse model for Alzheimer’s disease. Mutat. Res.661, 25–34 (2009).
- Grzanna R, Phan P, Polotsky A et al. Ginger extract inhibits β-amyloid peptide-induced cytokine and chemokine expression in cultured THP-1 monocytes. J. Altern. Complement Med.10, 1009–1013 (2004).
- Russo A, Palumbo M, Aliano C et al. Red wine micronutrients as protective agents in Alzheimer-like induced insult. Life Sci.72, 2369–2379 (2003).
- Conte A, Pellegrini S, Tagliazucchi D. Effect of resveratrol and catechins on PC12 tyrosine kinase activities and their synergistic protection from β-amyloid toxicity. Drugs Exp. Clin. Res.29, 243–255 (2003).
- Jang JH, Surh YJ. Protective effect of resveratrol on β-amyloid induced oxidative PC12 cell death. Free Radic. Biol. Med.34, 1100–1110 (2003).
- Savaskan E, Olivieri G, Meier F et al. Red wine ingredient resveratrol protects from β-amyloid neurotoxicity. Gerontology49, 380–383 (2003).
- Li MH, Jang JH, Sun B, Surh YJ. Protective effects of oligomers of grape seed polyphenols against β-amyloid-induced oxidative cell death. Ann. NY Acad. Sci.1030, 317–329 (2004).
- Han YS, Zheng WH, Bastianetto S et al. Neuroprotective effects of resveratrol against β-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br. J. Pharmacol.141, 997–1005 (2004).
- Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer’s disease amyloid-β peptides. J. Biol. Chem.280, 37377–37382 (2005).
- Kim YA, Lim SY, Rhee SH et al. Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in β-amyloid-treated C6 glioma cells. Int. J. Mol. Med.17, 1069–1075 (2006).
- Rivière C, Richard T, Quentin L et al. Inhibitory activity of stilbenes on Alzheimer’s β-amyloid fibrils in vitro. Bioorg. Med. Chem.15, 1160–1167 (2007).
- Wang J, Ho L, Zhao W et al. Grape-derived polyphenolics prevent Aβ oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer’s disease. J. Neurosci.28, 6388–6392 (2008).
- Karuppagounder SS, Pinto JT, Xu H et al. Dietary supplementation with resveratrol reduced plaque pathology in a transgenic model of Alzheimer’s disease. Neurochem. Intl54, 111–118 (2009).